3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
2
CNS
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Multiple Myeloma
11
Neoplasms, Plasma Cell
5
Waldenstrom Macroglobulinemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma
3
Sezary Syndrome
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Intraocular Lymphoma
2
Immunoglobulin Light-chain Amyloidosis
2
Immunoblastic Lymphadenopathy
2
Colonic Neoplasms
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
Therapeutics
5
Flow Cytometry
5
Cyclophosphamide
4
Polymerase Chain Reaction
3
Methylprednisolone
3
liposomal amphotericin B
2
Thiotepa
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Ondansetron
2
Melphalan
2
Itraconazole
2
Immunologic Techniques
2
Immunoenzyme Techniques
2
Etoposide
2
Dexamethasone
2
Caspofungin
2
Carmustine
2
Carboplatin
2
Calcium Dobesilate
2
Busulfan
2
Aprepitant
2
Amplified Fragment Length Polymorphism Analysis
2
Alemtuzumab
2
thymoglobulin
1
sargramostim
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Testicular Neoplasms
×
Drug Therapy
×
Plasma cell
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled